WallStSmart

Alphatec Holdings Inc (ATEC)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 8067% more annual revenue ($66.57B vs $815.05M). MRK leads profitability with a 4.8% profit margin vs -13.5%. ATEC appears more attractively valued with a PEG of 0.48. ATEC earns a higher WallStSmart Score of 42/100 (D).

ATEC

Hold

42

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 8.3Quality: 6.0
Piotroski: 5/9Altman Z: -1.68

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATECUndervalued (+35.1%)

Margin of Safety

+35.1%

Fair Value

$20.77

Current Price

$10.58

$10.19 discount

UndervaluedFair: $20.77Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATEC3 strengths · Avg: 9.3/10
PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Debt/EquityHealth
-50.0510/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.1%8/10

15.1% revenue growth

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

ATEC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.39B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-686.7%2/10

ROE of -686.7% — below average capital efficiency

Altman Z-ScoreHealth
-1.682/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ATEC

The strongest argument for ATEC centers on PEG Ratio, Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : ATEC

The primary concerns for ATEC are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ATEC profiles as a growth stock while MRK is a value play — different risk/reward profiles.

ATEC carries more volatility with a beta of 0.85 — expect wider price swings.

ATEC is growing revenue faster at 15.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ATEC scores higher overall (42/100 vs 36/100) and 15.1% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alphatec Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Alphatec Holdings, Inc., a medical technology company, designs, develops and advances technologies for the surgical treatment of spinal disorders. The company is headquartered in Carlsbad, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?